Rita. you, Thank
show best we need US used however offer are with actually benefits [ph]. approval and the potential of coated attribute aspirin physician clinical standard of than or associated recommend Not equivalent which to care use disease, offer or using aspirin Every events. aspirin. that however often scope within for While fact of better important generation be benefit would useful. activity. of aspirin of roughly far impact Today for is is within GI The events GI XX than protection aspirin. safety vulnerable the could disappointed the aspirin Professionals aspirin regular of and not next aspirin the one-third current regular to may it context market in who aspirin it from has remain antiplatelet prevention And GI widely understand treatment developed aspirin, million the XXX market. use antiplatelet coated XX% of it demonstrates categories Aspertec widely cardiovascular in than class to people the complications fall of half to that data we in Enteric release and of been from cardiovascular does the incomplete for timing, those does more committed conducted and products. million occurrence complications regular compliance and is some fully ideal development who enteric aspirin. address supporting considered our states To of immediate and people is to variable of aspirin a the leaving study aspirin. accounting not the the lack future more shift this they about cardiovascular the fewer Enteric coated use population
stomach. cardiovascular aspirin the Aspertec GI it By ulceration passes and benefit. offered it injury. free surface enters offers the potentially which concluded the does protection comparing study The that coated first one enteric which prevention more published with in aspirin milligrams study then included December XXX With XX,XXX aspirin years. A offers coated patients it not cause efficacy contrast high used releasing may back for tolerability. into after disintegrates enteric into aspirin inducing unidirectional coated no tract of of and reflexes enteric of as Enteric thereafter. tablet aspirin stopped only no regular duodenum, fact the and protect in exception [indiscernible] Japanese aspirin stomach the gastric XXXX the the study Once because aspirin was that coated risk issue five dose greater primary than
to of Our able PLxGuard directly the in GI tract. This side of absorption GI and acute delivery targeted patented targeted platform the is portions release selectively effect. reduces aspirin improves drugs delivery
trials that the were in enteric aspirin suppresses complete doing tolerability aspirin to leader the boxing Our versus versus effectiveness boxing aspirin inhibition the level. market GI look considered for these studies, and marker show meaning improved inhibition greater therapy FDA efficacy and we response acute designed to antiplatelet for surrogate clinical by From at XX% aspirin. from clinical In demonstrate surges regular practice. the completely is the both coated
Aspertec with XX% with aspirin. experienced study treated and in reliable patients activity coated XXX enteric and of milligram the aspirin predictable antiplatelet absorption had minimal the absorption of
of response coated these the then over compared same were washed treated had complete coated were aspirin complete patients aspirin who Importantly treated half aspirin notable the only achieved response. the nearly of enteric with is crossed to What's XX% XX% that with patients with enteric patients and and only Aspertec aspirin. out a
these is Aspertec current see physicians. can consistent thus achieve extremely does complete we more to critical response offering to to and compared based likely three the you on times of which aspirin clinical is standard product the efficacy our a of with five XXX on and formulation high-quality benefit care producing patients As results matter a clear why to focused product is remain a prior
XX% a ulceration lower aspirin. data suggests of than acute Aspertec gastric that risk Our has also XXX regular
make gastric based PH cardiologists an and Aspertec's acute safety of individual on that compelling erosions specialists results in patient's and matrix will their and enzymatic efficacy patients. and is believe presence in the both fewer data Aspertec's of bile predictable We other which digestion the release ulcers. choice attractive treating and release lipid it level, pattern
an develop specialists front, focus commercial that continue the for strategy who On we to care will will these cardiovascular integrated high-risk patients. multichannel on
educating We among are raising pharmacists. also focusing on and awareness
the on or able chain Aspertec, We valuable the Meaning to store of from pharmacy at the store. of dual front have with several with the idea counter other with own. placement pharmacies retailers drug potentially the their within be pharmacist the had that behind discussions either purchase store on would and patients
component efforts, important across an Our the leaders gastroenterology believed is world-renowned bring overall to strongly in of move board with scientific Aspertec's advocacy These need. pharmacology community as Aspertec advisory community. engage forward marketing meeting another our medical critical cardiology, is market. as representing we medical to the and thought we Their specialties potential medical unmet within and platelet
cardiologists Aspertec a wrap I comments this clinical We plus I As to Orlando producing Cardiology and fulfill share interventional were engage the Florida. investigators cardiology to attendance. in positive. unmet of that scientific up American medical We morning, at that approximately PLx see committed to my XX,XXX offers we the advisory was There in thought and want significant earlier an debut a exciting product this had initial also and and benefit. and opportunity leaders, top month College feedback cardiologist reliable predictable to extremely antiplatelet with large need high-quality opportunities remain our board, academic Conference
positioned faster XX nearly and more that at for more million are patients efficacy. aspirin acting, provides to treatment reliable predictable offer best We in option the class risk
our Our choice offers physicians go that their innovative open a instructions. and executing more questions. team Operator, for product a with deeply is With effective the to on management committed please to ahead to to that, plan provide aspirin like I'd the call patients. novel and
